CA3015347A1 - Formulations of antibody molecules to influenza virus - Google Patents

Formulations of antibody molecules to influenza virus Download PDF

Info

Publication number
CA3015347A1
CA3015347A1 CA3015347A CA3015347A CA3015347A1 CA 3015347 A1 CA3015347 A1 CA 3015347A1 CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A1 CA3015347 A1 CA 3015347A1
Authority
CA
Canada
Prior art keywords
formulation
seq
antibody molecule
sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015347A
Other languages
English (en)
French (fr)
Inventor
Susan Sloan
Bi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CA3015347A1 publication Critical patent/CA3015347A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3015347A 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus Pending CA3015347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299162P 2016-02-24 2016-02-24
US62/299,162 2016-02-24
PCT/US2017/019053 WO2017147248A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Publications (1)

Publication Number Publication Date
CA3015347A1 true CA3015347A1 (en) 2017-08-31

Family

ID=58264606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015347A Pending CA3015347A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Country Status (7)

Country Link
US (3) US20170240617A1 (https=)
EP (1) EP3419663A1 (https=)
JP (2) JP7104629B2 (https=)
CN (1) CN109195629A (https=)
AU (2) AU2017222564A1 (https=)
CA (1) CA3015347A1 (https=)
WO (1) WO2017147248A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SI3052192T1 (sl) 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3374390A1 (en) * 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) * 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN111393512B (zh) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
CN116589569B (zh) * 2023-03-06 2024-06-07 中国农业科学院兰州兽医研究所 一种抗h7n9亚型流感病毒ha蛋白的纳米抗体及其噬菌体展示文库的构建方法和应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
FI83662C (fi) 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2518607B2 (ja) 1985-08-29 1996-07-24 雪印乳業株式会社 インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1597350B1 (en) 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
HUE026793T2 (en) * 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
ES2372633T3 (es) 2003-11-04 2012-01-25 The Administrators Of The Tulane Educational Fund Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i.
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
JP4980895B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
CA2591992A1 (en) 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US7566454B2 (en) 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
WO2007089753A2 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
AU2007261196A1 (en) 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008073161A2 (en) 2006-08-14 2008-06-19 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
JP4625485B2 (ja) 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
US8030029B2 (en) 2007-01-23 2011-10-04 Academia Sinica Flu vaccines and methods of use thereof
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
CA2687147C (en) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008154813A1 (fr) 2007-06-15 2008-12-24 Xiamen University Anticorps monoclonaux se liant à l'hémagglutinine du virus de la grippe aviaire du sous type h5 et ses utilisations
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
AU2008297594B2 (en) 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
EP2207804B1 (en) 2007-09-13 2015-07-22 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
CA2705461A1 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
EP2250197B1 (en) 2008-02-05 2016-05-11 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses
WO2009111865A1 (en) 2008-03-12 2009-09-17 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
JP5586064B2 (ja) 2008-03-28 2014-09-10 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
FI20080333A0 (fi) 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
US20100061995A1 (en) 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
GB0818356D0 (en) 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
WO2010040281A1 (zh) 2008-10-09 2010-04-15 厦门大学 H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
CA2760553A1 (en) 2009-04-30 2010-11-04 Jr. James E. Crowe Monoclonal antibodies to influenza h1n1 virus and uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
WO2011003100A2 (en) 2009-07-02 2011-01-06 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
WO2011044570A2 (en) 2009-10-09 2011-04-14 Emory University Recombinant antibodies against h1n1 influenza
WO2011068143A1 (ja) 2009-12-03 2011-06-09 独立行政法人科学技術振興機構 Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2011210840B2 (en) 2010-01-27 2014-12-11 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
JPWO2011093217A1 (ja) 2010-01-29 2013-06-06 富士レビオ株式会社 抗Ｐａｎｄｅｍｉｃ（Ｈ１Ｎ１）２００９抗体及びそれを用いた免疫測定方法
WO2011096302A1 (ja) 2010-02-02 2011-08-11 国立大学法人名古屋大学 薬剤耐性インフルエンザウイルス特異的抗体及びその用途
JP2011160681A (ja) 2010-02-05 2011-08-25 Japan Science & Technology Agency Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
EP3098236A1 (en) 2010-03-08 2016-11-30 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
US20130022608A1 (en) 2010-03-26 2013-01-24 Pomona Ricerca S.R.L. FULL-LENGTH IgG IMMUNOGLOBULINS CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND USES THEREOF
KR101849738B1 (ko) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012026878A1 (en) 2010-08-23 2012-03-01 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
JP6029586B2 (ja) 2010-10-04 2016-11-24 マサチューセッツ インスティテュート オブ テクノロジー 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
WO2012072788A1 (en) 2010-12-02 2012-06-07 Mab-Factory Gmbh Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
CA2880791A1 (en) 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
WO2013044840A1 (zh) 2011-09-30 2013-04-04 中国科学院上海巴斯德研究所 高致病性禽流感的中和分子及其制备方法
JP5998222B2 (ja) 2011-09-30 2016-09-28 セルトリオン・インコーポレイテッド ヒトｂ細胞で生産されたインフルエンザａウイルス中和活性を持つ結合分子
WO2013059524A2 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
KR20130059721A (ko) 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
EP2785737A2 (en) 2011-12-02 2014-10-08 AIMM Therapeutics B.V. Influenza a virus specific antibodies
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
WO2013089496A1 (ko) 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
EP2814841A4 (en) 2012-01-31 2015-06-17 Univ Osaka HUMAN MONOCLONAL ANTIBODIES FOR WIDE PROTECTION AGAINST INFLUENZA B VIRUS AND METHOD OF USE THEREOF
SG11201405226TA (en) 2012-03-08 2014-11-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG11201406769RA (en) 2012-05-10 2014-11-27 Massachusetts Inst Technology Agents for influenza neutralization
WO2014011846A2 (en) * 2012-07-12 2014-01-16 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Wavelength and power scalable waveguiding-based infrared laser system
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US20140335504A1 (en) 2013-02-07 2014-11-13 Massachusetts Institute Of Technology Human adaptation of h5 influenza
SI3052192T1 (sl) 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
RU2682049C2 (ru) 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
ES2833230T3 (es) 2014-05-13 2021-06-14 Univ Pennsylvania Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021119467A1 (en) 2019-12-11 2021-06-17 Visterra, Inc. Compositions and methods for treating and preventing influenza

Also Published As

Publication number Publication date
JP2022110149A (ja) 2022-07-28
CN109195629A (zh) 2019-01-11
EP3419663A1 (en) 2019-01-02
US20170240617A1 (en) 2017-08-24
JP7104629B2 (ja) 2022-07-21
US12202885B2 (en) 2025-01-21
AU2017222564A1 (en) 2018-09-06
WO2017147248A1 (en) 2017-08-31
US20210054053A1 (en) 2021-02-25
US20200181243A1 (en) 2020-06-11
AU2024202246A1 (en) 2024-06-27
JP2019512012A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US12202885B2 (en) Formulations of antibody molecules to influenza virus
US12024552B2 (en) Ha binding agents
US10513553B2 (en) Compositions and methods for treating and preventing influenza
US11230593B2 (en) Compositions and methods for treating and preventing influenza
US20230257449A1 (en) Compositions and methods for treating and preventing influenza
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250522

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251117